Dr. Kunamneni is interested in the molecular mechanisms of how proteins work and function in biological pathways and have enjoyed contributing in the early stages of developing the Antibody Phage and Ribosome display libraries and tools for antibody discovery and engineering, exploratory PK, immunogenicity, and in vivo efficacy evaluation and enhancements aiming to treat diseases with unmet medical needs. His current focus is developing tools and technology for antibody discovery and engineering with the ultimate goal of generating antibody diagnostics and therapeutics with desired properties. Ribosome display platform has harnessed the humanization and affinity maturation stage, a clever molecular biology tool to give rapid affinity maturation—more rapid than any other ribosome display out there. That has meant applying knowledge of molecular biology to technology in a clever way. Our research projects include COVID-19, Ebola, Zika, Chronic Pain, Ischemic Stroke, Desmin Myopathy, Obesity-associated neuropathy, Breast Cancer, Autoimmune Disease, Thrombosis, etc. I am an author on 56 peer-reviewed papers, with 41 peer-reviewed primary research articles, 8 reviews, and 7 book chapters.